TY - JOUR
T1 - The Role of Nutraceuticals in Statin Intolerant Patients
AU - International Lipid Expert Panel (ILEP)
AU - Banach, Maciej
AU - Patti, Angelo Maria
AU - Giglio, Rosaria Vincenza
AU - Cicero, Arrigo F.G.
AU - Atanasov, Atanas G.
AU - Bajraktari, Gani
AU - Bruckert, Eric
AU - Descamps, Olivier
AU - Djuric, Dragan M.
AU - Ezhov, Marat
AU - Fras, Zlatko
AU - von Haehling, Stephan
AU - Katsiki, Niki
AU - Langlois, Michel
AU - Latkovskis, Gustavs
AU - Mancini, G. B.John
AU - Mikhailidis, Dimitri P.
AU - Mitchenko, Olena
AU - Moriarty, Patrick M.
AU - Muntner, Paul
AU - Nikolic, Dragana
AU - Panagiotakos, Demosthenes B.
AU - Paragh, Gyorgy
AU - Paulweber, Bernhard
AU - Pella, Daniel
AU - Pitsavos, Christos
AU - Reiner, Željko
AU - Rosano, Giuseppe M.C.
AU - Rosenson, Robert S.
AU - Rysz, Jacek
AU - Sahebkar, Amirhossein
AU - Serban, Maria Corina
AU - Vinereanu, Dragos
AU - Vrablík, Michal
AU - Watts, Gerald F.
AU - Wong, Nathan D.
AU - Rizzo, Manfredi
N1 - Publisher Copyright:
© 2018 American College of Cardiology Foundation
PY - 2018/7/3
Y1 - 2018/7/3
N2 - Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non–lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction.
AB - Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non–lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction.
KW - cardiovascular risk
KW - dyslipidemia
KW - nutraceuticals
KW - position paper
KW - statin intolerance
UR - https://www.scopus.com/pages/publications/85048895824
U2 - 10.1016/j.jacc.2018.04.040
DO - 10.1016/j.jacc.2018.04.040
M3 - Review article
C2 - 29957236
AN - SCOPUS:85048895824
SN - 0735-1097
VL - 72
SP - 96
EP - 118
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 1
ER -
SDG 3 Good Health and Well-being